Design of acute neuroprotection studies

Gregory W J Hawryluk, Ross Bullock

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is a substantial public health problem. The discovery of progressive, ongoing damage to the brain by means of complex molecular mechanisms which follow the initial injury has raised the possibility of targeted therapeutic intervention. Despite a substantial investment in trials testing dozens of therapeutics in humans, however, to date none has demonstrated robust efficacy. Deficiencies in the design of human clinical trials is likely to explain many translational failures, at least in part. Here we review secondary injury mediators and key trials which have targeted them. We provide a thorough discussion of putative reasons why trials thus far have failed and suggestions for the design of future clinical studies. Important insights from the IMPACT study are also presented in detail; in addition to providing critical insights for future trial design and analysis it suggests that reanalysis of completed studies may reveal inappropriately discarded treatments. Unfortunately limited resources are available for translational research and it is difficult to procure funds needed for well-resourced, large and definitive studies. History suggests, however, that investing in studies that are unlikely to provide a definitive answer only serves to increase required investment as they tend to mandate further study.

Original languageEnglish (US)
Pages (from-to)761-778
Number of pages18
JournalHandbook of Clinical Neurology
Volume128
DOIs
StatePublished - 2015

Fingerprint

Translational Medical Research
Wounds and Injuries
Financial Management
Public Health
History
Clinical Trials
Brain
Therapeutics
Neuroprotection
Clinical Studies
Traumatic Brain Injury

Keywords

  • Clinical trial
  • Design
  • Methodology
  • Neuroprotection
  • Traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Design of acute neuroprotection studies. / Hawryluk, Gregory W J; Bullock, Ross.

In: Handbook of Clinical Neurology, Vol. 128, 2015, p. 761-778.

Research output: Contribution to journalArticle

Hawryluk, Gregory W J ; Bullock, Ross. / Design of acute neuroprotection studies. In: Handbook of Clinical Neurology. 2015 ; Vol. 128. pp. 761-778.
@article{8a8a2effc148459fa59d94ee3d41ba54,
title = "Design of acute neuroprotection studies",
abstract = "Traumatic brain injury (TBI) is a substantial public health problem. The discovery of progressive, ongoing damage to the brain by means of complex molecular mechanisms which follow the initial injury has raised the possibility of targeted therapeutic intervention. Despite a substantial investment in trials testing dozens of therapeutics in humans, however, to date none has demonstrated robust efficacy. Deficiencies in the design of human clinical trials is likely to explain many translational failures, at least in part. Here we review secondary injury mediators and key trials which have targeted them. We provide a thorough discussion of putative reasons why trials thus far have failed and suggestions for the design of future clinical studies. Important insights from the IMPACT study are also presented in detail; in addition to providing critical insights for future trial design and analysis it suggests that reanalysis of completed studies may reveal inappropriately discarded treatments. Unfortunately limited resources are available for translational research and it is difficult to procure funds needed for well-resourced, large and definitive studies. History suggests, however, that investing in studies that are unlikely to provide a definitive answer only serves to increase required investment as they tend to mandate further study.",
keywords = "Clinical trial, Design, Methodology, Neuroprotection, Traumatic brain injury",
author = "Hawryluk, {Gregory W J} and Ross Bullock",
year = "2015",
doi = "10.1016/B978-0-444-63521-1.00047-9",
language = "English (US)",
volume = "128",
pages = "761--778",
journal = "Handbook of Clinical Neurology",
issn = "0072-9752",
publisher = "Elsevier",

}

TY - JOUR

T1 - Design of acute neuroprotection studies

AU - Hawryluk, Gregory W J

AU - Bullock, Ross

PY - 2015

Y1 - 2015

N2 - Traumatic brain injury (TBI) is a substantial public health problem. The discovery of progressive, ongoing damage to the brain by means of complex molecular mechanisms which follow the initial injury has raised the possibility of targeted therapeutic intervention. Despite a substantial investment in trials testing dozens of therapeutics in humans, however, to date none has demonstrated robust efficacy. Deficiencies in the design of human clinical trials is likely to explain many translational failures, at least in part. Here we review secondary injury mediators and key trials which have targeted them. We provide a thorough discussion of putative reasons why trials thus far have failed and suggestions for the design of future clinical studies. Important insights from the IMPACT study are also presented in detail; in addition to providing critical insights for future trial design and analysis it suggests that reanalysis of completed studies may reveal inappropriately discarded treatments. Unfortunately limited resources are available for translational research and it is difficult to procure funds needed for well-resourced, large and definitive studies. History suggests, however, that investing in studies that are unlikely to provide a definitive answer only serves to increase required investment as they tend to mandate further study.

AB - Traumatic brain injury (TBI) is a substantial public health problem. The discovery of progressive, ongoing damage to the brain by means of complex molecular mechanisms which follow the initial injury has raised the possibility of targeted therapeutic intervention. Despite a substantial investment in trials testing dozens of therapeutics in humans, however, to date none has demonstrated robust efficacy. Deficiencies in the design of human clinical trials is likely to explain many translational failures, at least in part. Here we review secondary injury mediators and key trials which have targeted them. We provide a thorough discussion of putative reasons why trials thus far have failed and suggestions for the design of future clinical studies. Important insights from the IMPACT study are also presented in detail; in addition to providing critical insights for future trial design and analysis it suggests that reanalysis of completed studies may reveal inappropriately discarded treatments. Unfortunately limited resources are available for translational research and it is difficult to procure funds needed for well-resourced, large and definitive studies. History suggests, however, that investing in studies that are unlikely to provide a definitive answer only serves to increase required investment as they tend to mandate further study.

KW - Clinical trial

KW - Design

KW - Methodology

KW - Neuroprotection

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84924956319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924956319&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63521-1.00047-9

DO - 10.1016/B978-0-444-63521-1.00047-9

M3 - Article

C2 - 25701919

AN - SCOPUS:84924956319

VL - 128

SP - 761

EP - 778

JO - Handbook of Clinical Neurology

JF - Handbook of Clinical Neurology

SN - 0072-9752

ER -